As Chief Audit Officer of Novartis, Teresa and her team provide risk-based assurance and advice on key strategic topics to the Board and management, acting as a key partner to the organization to help ...

We are excited to welcome the talented team at Regulus to Novartis as we continue to build on our pipeline in renal disease with high unmet medical need.” Farabursen is an investigational ...

Innovation enables faster adaptation and response to changes, promotes growth, and distinguishes a company from its competitors. The foundation of breakthrough innovations and good science are diverse ...

Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis works closely with healthcare professionals around the world to support ...

Inclusion Criteria for core period: 1. Male and female participants ≥18 years of age at the time of signing of the ICFs 2. Confirmed CINDU diagnosis (as per guidelines) for symptomatic dermographism, ...

Key Inclusion Criteria: 1. Male and female participants ≥ 18 years of age at the time of signing of the informed consent. 2. Diagnosis of HS based on clinical history and physical examination for at ...

What is Novartis Managed Access? There are instances where a patient has a serious or life-threatening disease or condition, for which all currently available treatment options have been exhausted and ...

The purpose of this study is to evaluate the effect of two different doses of ianalumab versus placebo in addition to first-line corticosteroids in maintaining platelet count ≥30 G/L in adult ...

Key Inclusion Criteria: * 18 years and older at time of signing consent * Patients with primary or secondary wAIHA documented by positive direct antiglobulin test specific for anti-IgG or anti-IgA, ...

An International, Prospective, Open-label, Multi-center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease ...

Careers at Novartis in Slovenia. At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to ...

This is a multicenter, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early-stage ALS (within 2 years of ...